{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002887","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.139445+00:00","generated_at":"2026-06-15T23:35:51.739234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies","bullets":["Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).","Cash, equivalents & securities $278.4M at March 31, 2023; sufficient through 2025.","Phase 2 CSU enrollment completion expected Q3 2023; topline data late 2023/Q1 2024.","Phase 2 EoE study initiation expected June 2023; CDX-585 enters clinic mid-2023.","R&D expenses $26.8M (up from $17.1M) driven by barzolvolimab trials and manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002887","json":"https://secwatch.observer/filing/0001171843-23-002887.json","markdown":"https://secwatch.observer/filing/0001171843-23-002887.md","text":"https://secwatch.observer/filing/0001171843-23-002887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/0001171843-23-002887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/f8k_050423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:35:51.739234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb80cc545235f4ec6a64328d077194ee7a4c5a0c","claim":"Celldex Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/0001171843-23-002887-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}